We had the pleasure to talk to Janine Simons (Erasmus University Medical Center, Rotterdam, Netherlands) about the RISAS study and its findings (Clinical Trial Identifier: NCT02800317). The abstract ‘Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial‘ (ABSTRACT NUMBER: GS1-10) was presented at the virtual SABCS 2020, 8-11 December 2020.
- Could you tell us a little about radioactive iodine seed localisation and the history of its use to date in breast cancer therapy?
- What was the rationale for combining radioactive iodine seed localisation in the axilla with the sentinel node procedure (RISAS) for cancer staging after neoadjuvant chemotherapy?
- Could you give us an overview of the RISAS study and its findings?
- What are the implications of these findings for clinical practice?
- How do you expect the use of radioactive seed localisation to develop in the future?
Speaker Disclosures: Dr Janine Simons has nothing to disclose in relation to this video interview. Dr Janine Simons was previously at the Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands, where the RISAS study was conducted.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the San Antonio Breast Cancer Symposium (SABCS) 2020.
Share this Video
Related Videos In Breast Cancer
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Javier Cortes, SABCS 2020 – Pembrolizumab in Triple-negative Breast Cancer
touchONCOLOGY joins Dr Javier Cortes at the San Antonio Breast Cancer Symposium (SABCS) 2020, to discuss the data being presented around the KEYNOTE-355 study and the potential of pembrolizumab as a treatment for triple-negative breast cancer (Clinical Trial Identifier: NCT02819518). The abstract ‘Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!